Enlivex Therapeutics Ltd. ENLV.TA Stock
Enlivex Therapeutics Ltd. Price Chart
Enlivex Therapeutics Ltd. ENLV.TA Financial and Trading Overview
| Enlivex Therapeutics Ltd. stock price | 570.6 ILA |
| Previous Close | 965.9 ILA |
| Open | 1000 ILA |
| Bid | 941.6 ILA x N/A |
| Ask | 942.2 ILA x N/A |
| Day's Range | 972.2 - 1000 ILA |
| 52 Week Range | 941.3 - 1951 ILA |
| Volume | 13.66K ILA |
| Avg. Volume | 14.46K ILA |
| Market Cap | 186.22M ILA |
| Beta (5Y Monthly) | 0.60495 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.52 ILA |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ENLV.TA Valuation Measures
| Enterprise Value | 135.08M ILA |
| Trailing P/E | N/A |
| Forward P/E | -8.628319 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 315.94296 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.399 |
Trading Information
Enlivex Therapeutics Ltd. Stock Price History
| Beta (5Y Monthly) | 0.60495 |
| 52-Week Change | -28.12% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1951 ILA |
| 52 Week Low | 941.3 ILA |
| 50-Day Moving Average | 1046.49 ILA |
| 200-Day Moving Average | 1388.02 ILA |
ENLV.TA Share Statistics
| Avg. Volume (3 month) | 14.46K ILA |
| Avg. Daily Volume (10-Days) | 11.88K ILA |
| Shares Outstanding | 18.57M |
| Float | 14.8M |
| Short Ratio | N/A |
| % Held by Insiders | 11.82% |
| % Held by Institutions | 9.75% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.80% |
| Return on Equity (ttm) | -43.78% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -25020000 ILA |
| Net Income Avi to Common (ttm) | -31060000 ILA |
| Diluted EPS (ttm) | -6.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 50.24M ILA |
| Total Cash Per Share (mrq) | 2.73 ILA |
| Total Debt (mrq) | 4.85M ILA |
| Total Debt/Equity (mrq) | 8.53 ILA |
| Current Ratio (mrq) | 7.92 |
| Book Value Per Share (mrq) | 3.086 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -23953000 ILA |
| Levered Free Cash Flow (ttm) | -18677124 ILA |
Profile of Enlivex Therapeutics Ltd.
| Country | Israel |
| State | N/A |
| City | Ness Ziona |
| Address | 14 Einstein Street |
| ZIP | 7403618 |
| Phone | 972 8 662 3301 |
| Website | https://www.enlivex.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Q&A For Enlivex Therapeutics Ltd. Stock
What is a current ENLV.TA stock price?
Enlivex Therapeutics Ltd. ENLV.TA stock price today per share is 570.6 ILA.
How to purchase Enlivex Therapeutics Ltd. stock?
You can buy ENLV.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Enlivex Therapeutics Ltd.?
The stock symbol or ticker of Enlivex Therapeutics Ltd. is ENLV.TA.
Which industry does the Enlivex Therapeutics Ltd. company belong to?
The Enlivex Therapeutics Ltd. industry is Biotechnology.
How many shares does Enlivex Therapeutics Ltd. have in circulation?
The max supply of Enlivex Therapeutics Ltd. shares is 222.96K.
What is Enlivex Therapeutics Ltd. Price to Earnings Ratio (PE Ratio)?
Enlivex Therapeutics Ltd. PE Ratio is now.
What was Enlivex Therapeutics Ltd. earnings per share over the trailing 12 months (TTM)?
Enlivex Therapeutics Ltd. EPS is -5.52 ILA over the trailing 12 months.
Which sector does the Enlivex Therapeutics Ltd. company belong to?
The Enlivex Therapeutics Ltd. sector is Healthcare.